Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

주식 순위 #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
주가
$6.89
시가총액
$43.94B
변동 (1일)
-2.91%
변동 (1년)
-24.78%
국가
CN
거래 Jiangsu Hengrui Medicine Co., Ltd. (600276)

카테고리

Healthcare
Jiangsu Hengrui Medicine Co., Ltd. (600276)의 수익
2026 기준 수익 TTM: 0
Jiangsu Hengrui Medicine Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Jiangsu Hengrui Medicine Co., Ltd.의 수익 기록 (2001 ~ 2026)
연말 수익
연도 수익 변화
2025 $1.24B 26.71%
2024 $982.27M 48.98%
2023 $659.33M 14.60%
2022 $575.32M -18.13%
2021 $702.70M -33.43%
2020 $1.06B 21.37%
2019 $869.67M 32.96%
2018 $654.07M 13.20%
2017 $577.79M 33.13%
2016 $433.99M 10.00%
2015 $394.53M 35.79%
2014 $290.55M 19.20%
2013 $243.75M 12.88%
2012 $215.93M 27.81%
2011 $168.94M 29.63%
2010 $130.33M 13.97%
2009 $114.35M 66.01%
2008 $68.88M -1.66%
2007 $70.05M 89.01%
2006 $37.06M 35.54%
2005 $27.34M 31.05%
2004 $20.86M 14.58%
2003 $18.21M 36.38%
2002 $13.35M 13.13%
2001 $11.80M 0.00%
유사 기업 또는 경쟁사의 수익